回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301093 证券简称：华兰股份 公告编号：2025-078 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025年 7月 12日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份的回 购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募资金不 ...

关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第二十七次 会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置募集资金和自 有资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 130,000 万元的 闲置募集资金（含超募资金，下同）和自有资金进行现金管理，其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效期为公司股东大会审议通 过之日起 12 个月内，上述额度在有效期内可循环滚动使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯网（www.cninfo.com.cn）上披露 的《关于使用部分闲置募集资金和自有资金进行现金管理的公告》（公告编号：2024- 111）。 近日，公司子公司开立了募集资金现金管理产品专用结算账户，现就具体情况公 告如下： 证券 ...

最新一期业绩显示，2025年一季报，公司实现营业收入1.46亿元，同比15.03%；净利润1837.92万元， 同比72.10%，销售毛利率37.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13华兰股份74.9186.551.9042.91亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.41亿11三鑫医疗 20.0220.033.2945.55亿12鱼跃医疗20.0519.662.71355.08亿 来源：金融界 7月29日，华兰股份今日收 ...

Industry Overview - As of July 17, the medical device industry rose by 0.78%, with a net capital outflow of 178.58 million [1] - A total of 89 stocks in the sector increased, while 31 stocks decreased [1] Top Decliners - The top ten decliners in the sector included: - ST Kelly (-6.72%) - Haooubo (-4.36%) - Tailin Biology (-2.04%) - Mountain Outside Mountain (-1.71%) - Botuo Biology (-1.59%) - Yirui Technology (-1.35%) - DR Sanyou Medical (-1.31%) - Jihigh Development (-1.24%) - Anxu Biology (-1.21%) - Aidi Te (-0.89%) [1][1] Notable Gainers - Notable gainers included: - Anjisi: 7.36% increase with a net capital outflow of 12.83 million - Hualan Co.: 5.22% increase with a net capital outflow of 5.90 million - Xinmai Medical: 5.11% increase with a net capital inflow of 6.21 million - Nanwei Medical: 4.45% increase with a net capital inflow of 19.79 million [1][1][1] Market Sentiment - The overall market sentiment in the medical device sector showed a mixed performance with significant capital outflows from certain stocks while others attracted investment [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-076 江苏华兰药用新材料股份有限公司 关于公司取得金融机构股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 本次回购股份的基本情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Group 1 - National Bureau of Statistics will hold a press conference to introduce the national economic operation situation for the first half of 2025 [2] - The housing price data for 70 major cities in June will be released [4] - Domestic refined oil prices are expected to see their sixth decrease of the year, with a total adjustment pattern of "six increases, five decreases, and two pauses" so far this year [5] Group 2 - New regulations for individual business registration management will take effect, allowing individual businesses to transition to enterprises while retaining their social credit codes and other identifiers [6] - A total of 3.17 billion shares worth 4.246 billion yuan will be unlocked today, with several companies seeing significant share unlocks [7][8] - 20 companies have disclosed stock repurchase progress, with several companies announcing significant repurchase amounts [9]

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. plans to repurchase its shares using raised funds, self-owned funds, and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million [1][2]. Summary by Sections Share Repurchase Plan - The company will use a total of no less than RMB 100 million and no more than RMB 200 million for the share repurchase, with raised funds accounting for no less than RMB 70 million and no more than RMB 140 million [2]. - The maximum repurchase price is set at RMB 45.50 per share, with the repurchase period not exceeding 12 months from the date of shareholder meeting approval [2]. Adjustments Post-Equity Distribution - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price will be adjusted to RMB 34.84 per share, effective from July 14, 2025 [3]. - The repurchase will include shares for employee stock ownership plans or equity incentives, with specific quantities and funding sources detailed in the report [3][4]. Debt Creditor Information - Creditors have the right to request debt repayment or guarantees within 30 days of notification or 45 days from the announcement date, with the company continuing to fulfill obligations as per original debt agreements [4][5]. - Required materials for debt claims include contracts and identification documents, with specific submission methods outlined [5].

证券代码：301093 证券简称：华兰股份 公告编号：2025-075 江苏华兰药用新材料股份有限公司 关于回购股份减少注册资本通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 通知债权人的原由 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025年 7月 12日在巨潮资讯网（www.cninfo.com.cn）上披露的《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份的回 购报告书》（以下简称"《回购报告书》"）。 根据公司《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集 中竞价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含），其中超募资金不低于人民币 ...

公司于 2025年 6月 23日召开了第六届董事会第二次会议，审议通过了《关 于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份方案 的议案》，该议案已经公司于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会 逐项审议通过。具体内容详见公司于 2025 年 7 月 12 日在巨潮资讯网 （www.cninfo.com.cn）上披露的《关于使用超募资金、自有资金及自筹资金以 集中竞价交易方式回购公司股份的回购报告书》（以下简称"《回购报告书》"）。 证券代码：301093 证券简称：华兰股份 公告编号：2025-074 江苏华兰药用新材料股份有限公司 关于 2024 年年度权益分派实施后调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 江苏华兰药用新材料股份有限公司（以下简称"公司"）2024年年度权益分 派实施后，公司使用超募资金、自有资金及自筹资金以集中竞价交易方式回购 股份的价格上限由不超过人民币 45.50 元/股（含）调整为不超过人民币 34.84 元 /股（含）。公司本次对回购股 ...

[2025 Semi-Annual Performance Forecast](index=1&type=section&id=Jiangsu%20Hualan%20Pharmaceutical%20New%20Material%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Forecast) [Performance Forecast Overview](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates a year-on-year increase in its 2025 first-half performance, with net profit attributable to shareholders projected between 38 million CNY and 49.4 million CNY, representing a 2.77% to 33.60% growth, and non-recurring net profit between 30 million CNY and 39 million CNY, up 22.50% to 59.25% Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Profit: 38.00 million CNY - 49.40 million CNY | Profit: 36.9762 million CNY | | Year-on-Year Change | Increase: 2.77% — 33.60% | - | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Profit: 30.00 million CNY - 39.00 million CNY | Profit: 24.4894 million CNY | | Year-on-Year Change | Increase: 22.50% — 59.25% | - | | **Basic Earnings Per Share** | Profit: 0.30 CNY/share - 0.39 CNY/share | Profit: 0.29 CNY/share | [Reasons for Performance Change](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Change) During the reporting period, the company's performance growth was primarily driven by enhanced market development and expanded sales channels, leading to a simultaneous increase in sales orders, revenue, and gross profit - The core drivers of the company's performance growth are market development and sales channel expansion, directly leading to an increase in sales orders, sales revenue, and gross profit compared to the prior period[6](index=6&type=chunk) [Risk Warning and Disclaimer](index=1&type=section&id=II.%20Communication%20with%20Accounting%20Firm) The company's preliminary, unaudited performance forecast has been pre-communicated with auditors without disagreement, with final figures subject to the official 2025 semi-annual report, urging investor caution - This performance forecast data represents preliminary estimates by the company's finance department and remains unaudited[4](index=4&type=chunk)[7](index=7&type=chunk) - The company has pre-communicated with the annual report auditing accounting firm regarding this performance forecast, with no disagreements identified[4](index=4&type=chunk) - The company advises investors that specific financial data will be subject to the officially disclosed 2025 semi-annual report, urging cautious decision-making and awareness of investment risks[7](index=7&type=chunk)